Overview
Establishing Multidisciplinary Clinical Pathways for Selecting and Sequencing Systemic Treatments for Moderate to Severe Atopic Dermatitis
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Nearly half of patients with atopic dermatitis (AD) have moderate to severe disease with symptoms that negatively affect their sleep, mental health, and overall quality of life. Although the clinical heterogeneity of AD is increasingly recognized, failure to assess AD in routine clinical practice can lead to delayed diagnosis, underappreciation of disease severity, and delays in treatment initiation.
Topical therapies can be very effective in treating mild cases of AD, but patients with moderate to severe disease generally require systemic therapy to achieve long-term disease control. The discovery of the role of type 2 inflammatory pathways in AD has led to new concepts in AD pathogenesis, and subsequently, to novel treatment strategies. Yet evidence indicates that there is discordance between patients’ and clinicians’ perception of severity and disease burden, and many patients report inadequate disease control with current treatments.
To personalize treatment of moderate to severe AD, clinicians must continually assess and adapt to evolving diagnostic and therapeutic strategies to ensure proactive, targeted, and patient-centric treatment to improve outcomes. To support translation and implementation of the latest evidence into routine clinical practice, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to facilitate peer-to-peer learning with their interprofessional clinical teams.
This program is intended for dermatologists, allergists, immunologists, internists, pediatricians, APPs, nurses, clinical and community pharmacists and other members of the multidisciplinary team who treat diverse patients with AD.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting up to 20% of children and up to 10% of adults. Symptoms of AD may present at any age, with up to 20% of young adults aged 18 to 29 years presenting with a new onset of symptoms and up to 80% of children may experience AD symptoms into adulthood, suggesting that AD is a life-long disease. In addition, AD is commonly accompanied by comorbid asthma and/or other atopic conditions such as allergic rhinitis, and it can also be accompanied by a variety of systemic diseases, such as autoimmune disorders, eosinophilic gastroenteritis, inflammatory bowel disease, nephritic syndrome, and metabolic diseases. Of greater concern to patients is the significant impact of AD on quality of life, although there is frequently a disconnect between patients and clinicians in perception of disease severity and disease burden. Unfortunately, AD treatment can be challenging due to heterogeneity in its natural course as well as unpredictable individual trajectories, leading to suboptimal disease control even with effective therapeutic options for moderate to severe disease. Moreover, evidence indicates that systemic therapy for moderate to severe AD remains underutilized and large percentages of healthcare providers fail to adhere to treatment recommendations. Consequently, clinicians treating patients with moderate to severe AD will benefit from this comprehensive education program covering topics including, but not limited to, disease burden, clinical features, assessment of disease severity, efficacy and safety of systemic therapies for moderate to severe disease, and patient cases demonstrating considerations for the individualization of therapy.
Upon completion of this activity, learners will be able to:
•Apply recent treatment guidelines and the latest clinical trial data for the systemic treatment of moderate-to-severe AD
•Outline the MOAs and latest clinical evidence for novel systemic therapies for the treatment of moderate-to-severe AD
•Discuss the therapeutic potential of novel therapies in addressing unmet needs for the treatment of moderate-to-severe AD in diverse patient populations.
•Develop current and future treatment algorithms to optimally select and sequence therapies for diverse patients with moderate-to-severe AD
•Apply recent treatment guidelines and the latest clinical trial data for the systemic treatment of moderate-to-severe AD
•Outline the MOAs and latest clinical evidence for novel systemic therapies for the treatment of moderate-to-severe AD
•Discuss the therapeutic potential of novel therapies in addressing unmet needs for the treatment of moderate-to-severe AD in diverse patient populations.
•Develop current and future treatment algorithms to optimally select and sequence therapies for diverse patients with moderate-to-severe AD
Content Topics
- What do I need to know about AD and how to manage it?
- What factors contribute to AD onset?
- How should moderate-to-severe AD be treated?
- How can treatment selection be optimized for each patient?
- What are strategies practices can use to improve patient car
This educational activity is presented in collaboration with Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by educational grants from Lilly and Pfizer.
Jonathan Silverberg, MD, PhD, MPH
Professor of Dermatology
Director of Clinical Research
Director of Patch Testing
Department of Dermatology
George Washington University School of Medicine and Health Sciences
Washington, DC
Professor of Dermatology
Director of Clinical Research
Director of Patch Testing
Department of Dermatology
George Washington University School of Medicine and Health Sciences
Washington, DC
Kelly Dugan, PharmD, BCPS, CSP
Clinical Pharmacy Specialist
Rush University Medical Center
Chicago, IL
It is the policy of the Interprofessional Continuing Education office at Rush to ensure that its CE activities are independent, free of commercial bias. Therefore, we manage all financial relationships associated with accredited continuing education activities. RUSH asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. There is no minimum threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of relationships to education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the planning, implementation, or evaluation of the continuing education activity. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
Individuals in control of content for this activity have the following relevant financial relationships with ineligible companies to disclose and all financial relationships have been mitigated.
The following financial relationships have been provided:
Jonathan Silverberg, MD, PHD, MPH
Research Grant: Abbvie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Attovia, Boehringer-Ingelheim, Bristell-Meyers Squibb, Castle Biosciences, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, FIDE, Formation Bio, Galderma, GlaxoSmithKline, Immunocore, Incyte, Inmagene, Invea, Leo Pharma, Merck, Nektar, Novartis, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, TARGET-RWE, Teva, Triveni, UCB, Union, UpToDate
Speakers' Bureau: Abbvie, Arcutis, Dermavant, Eli Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Kelly Dugan, PharmD, BCPS, CSP
No financial relationships to disclose
Staff Members of the Office of Interprofessional Continuing Education at Rush University Medical Center, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: baricitinib, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, ivarmacitinib, jaktinib, rocatinlimab, amlitelimab, rademikibart, and akesobio are not approved by the US Food and Drug Administration for the treatment of atopic dermatitis. Abrocitinib and upadacitinib are not approved by the US Food and Drug Administration for first-line systemic treatment of atopic dermatitis.
To receive credit, learners are required to complete the assessment, view the content, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Rush University Medical Center designates this enduring material for a maximum of 2.5 nursing contact hour(s).
Rush University Medical Center designates this application-based activity for a maximum of 2.5 contact hour(s) for pharmacists. ACPE Universal Activity Number: JA0000275-0000-25-261-H01-P
Successful completion of this CME activity, which includes participation in the evaluation component, enables the the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted on the first day of each month.
